Start Submission Become a Reviewer

Reading: Systemic Therapy for Cardiac Sarcomas

Download

A- A+
Alt. Display

Review Articles

Systemic Therapy for Cardiac Sarcomas

Authors:

Vinod Ravi ,

The University of Texas MD Anderson Cancer Center, Houston, Texas, US
About Vinod
M.D.
X close

Robert S. Benjamin

The University of Texas MD Anderson Cancer Center, Houston, Texas, US
About Robert S.
M.D.
X close

Abstract

Introduction

Cardiac sarcomas create 2 risks: local problems and metastatic disease. Most frequently, the histologies are angiosarcoma and high-grade pleomorphic unclassified sarcoma (formerly called MFH or malignant fibrous histiocytoma). There is also a clinical-pathological entity without distinctive histological features of tumors that originate in the pulmonary artery and are referred to as pulmonary artery sarcomas or intimal sarcomas of the pulmonary artery. Conventional wisdom indicates that soft-tissue sarcomas are poorly responsive to chemotherapy. Luckily, that is not the case. Attempts to concentrate on the local problem only with therapies up to and including cardiac transplantation have been unsuccessful due to the high rate of fatal metastatic disease.

How to Cite: 1. Ravi V, Benjamin RS. Systemic Therapy for Cardiac Sarcomas. Methodist DeBakey Cardiovascular Journal. 2010;6(3):57-60. DOI: http://doi.org/10.14797/mdcvj.222
Published on 01 Jul 2010.
Peer Reviewed

Downloads

  • PDF (EN)